NEW DELHI, Juun 22 (Xinhua) - Shirkadda sameysa tallaalka Hindiya ee Bharat Biotech Covaxin ayaa muujisay waxtar boqolkiiba 77.8 ah tijaabooyinka wejiga saddexaad, sida ay ku warrameen warbaahinta maxalliga ah Talaadadii.
"Covaxin-ka Bharat Biotech wuxuu 77.8 boqolkiiba waxtar u leeyahay ka hortagga COVID-19, sida laga soo xigtay xogta laga helay tijaabooyinka wejiga III ee lagu sameeyay 25,800 oo kaqeybgale oo ku baahsan Hindiya," ayaa lagu yiri warbixin.
Heerka waxtarka ayaa soo baxay Talaadadii ka dib markii guddiga khubarada ee khuseysa maareynta dawooyinka ee guud ahaan Hindiya (DCGI) (SEC) ay kulmeen oo ay ka wada hadleen natiijooyinka.
Shirkadda dawooyinka ayaa xogta tijaabada wejiga saddexaad ee tallaalka u gudbisay DCGI dhammaadka usbuuca.
Warbixinnada ayaa sheegaya in shirkadda la filayo inay kulan "hordhac ah" la yeelato mas'uuliyiinta Hay'adda Caafimaadka Adduunka Arbacada, si ay uga wada hadlaan tilmaamaha ku saabsan soo gudbinta ugu dambeysa ee xogta iyo dukumentiyada loo baahan yahay.
Hindiya waxay bilowday tallaalka ballaaran ee ka dhanka ah COVID-19 Janaayo 16 iyadoo bixisay laba tallaal oo lagu sameeyay Hindiya, kuwaas oo kala ah Covishield iyo Covaxin.
Machadka Serum ee Hindiya (SII) ayaa soo saaraya Covishield ee Jaamacadda AstraZeneca-Oxford, halka Bharat Biotech ay iskaashi la samaysay Golaha Cilmi-baarista Caafimaadka ee Hindiya (ICMR) si ay u soo saaraan Covaxin.
Tallaalka Sputnik V ee Ruushka lagu sameeyay ayaa sidoo kale laga hirgeliyay dalka.
Waqtiga boostada: Juun-25-2021